English
Back
Download
Log in to access Online Inquiry
Back to the Top

Therapeutics Company Announces Collaboration With Oncology Firm

Haystack Oncology and Lisata Therapeutics Collaborate on Evaluating Pancreatic Cancer Therapy Efficacy Using MRD Technology.
Haystack Oncology announced a research collaboration with Lisata Therapeutics Inc. This partnership aims to leverage Haystack's cutting-edge minimal residual disease (MRD) technology to assess the efficacy of innovative treatments for metastatic pancreatic cancer. $Lisata Therapeutics (LSTA.US)$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
Translate
Report
3757 Views
Comment
Sign in to post a comment
    254
    Followers
    0
    Following
    537
    Visitors
    Follow